medigraphic.com
Instituto Nacional de Salud Pública

2008, Number 2

<< Back Next >>

salud publica mex 2008; 50 (2)

Generalized cost-effectiveness of preventive interventions against cervical cancer in Mexican women: Results of a Markov model from the public sector perspective

Gutiérrez-Delgado C, Báez-Mendoza C, González-Pier E, Prieto de la RA, Witlen R

Language: Spanish
References: 40
Page: 107-118
PDF size: 215.48 Kb.


ABSTRACT

Objective. To develop a generalized cost-effectiveness analysis (GCEA) of the HPV vaccine, hybrid capture screening (HC) and Papanicolaou screening (Pap) in the Mexican context. Materials and Methods. From April to August 2007, in Mexico, a GCEA of the interventions was developed for 10 possible scenarios using a Markov model from the public sector perspective as payer. Results. Scenarios considering 80% coverage show an ACER per DALY averted of $16 678 pesos for Pap of women between ages 25 and 64, $17 277 pesos for HC of women between ages 30 and 64, and $84 008 pesos for vaccination of 12-year-old girls. Annual financing of $621, $741 and $2 255 million pesos, respectively, is needed for these scenarios. Conclusions. A selective, combined introduction of Pap-HC screening that considers the comparative advantages of application in different populations and geographical areas is suggested. Additionally, it is suggested to introduce the vaccine once a threshold price of $181 pesos per dose –when the vaccine becomes equal in terms of costeffectiveness to HC– has been achieved.


REFERENCES

  1. Secretaría de Salud. Principales causas de mortalidad en mujeres 2005. Disponible en: http://sinais.gob.mx. Consultado en abril de 2007.

  2. Bosch X, Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Nat Cancer Inst Monogr 2003;31.

  3. Alliance for Cervical Cancer Prevention. Natural history of cervical cancer. Disponible en: www.path.org/files/RH_natural_history_of_cc_fs.pdf. [Consultado abril 2007].

  4. Dunne E. HPV vaccines. Disponible en: njlmn.rutgers.edu/cdr/docs/02-HPVVaccines_Dunne.pdf. [Consultado abril 2007].

  5. Subsecretaría de Promoción y Prevención de la Salud. NOM-014-SSA2-1994: Sobre el control y tratamiento del cáncer cérvico-uterino. México: Secretaría de Salud, Diario Oficial de la Federación, 31 de mayo de 2007.

  6. Instituto Nacional de Salud Pública. Autotoma vaginal en casa para identificación de ADN de VPH y su utilidad en la detección oportuna de cáncer cervical: una intervención en usuarias del Seguro Popular. México: Instituto Nacional de Salud Pública, 2006.

  7. Centro Nacional de Equidad de Género y Salud Reproductiva. Informe de rendición de cuentas de la administración 2000-2006; etapa 3: informe que comprende del 1 de diciembre 2000 al 30 de noviembre 2006. México: Centro Nacional de Equidad de Género y Salud Reproductiva, 2007.

  8. Subsecretaría de Promoción y Prevención de la Salud. Programa de acción: cáncer cérvico-uterino. México: Secretaría de Salud, 2002.

  9. Lazcano-Ponce E, Castro R, Allen B, Najera P, Alonso de Ruiz P, Hernandez-Avila M. Barriers to early detection of cervical-uterine cancer in Mexico. J Women Health 1999;8(3):399-408.

  10. Secretaría de Salud. Sistema de protección social en salud: elementos conceptuales, financieros y operativos. 2a ed. México: Fondo de Cultura Económica, 2006.

  11. Tan-Torres T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, et al. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.

  12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:19.

  13. Garnett G, Kim J, French K, Goldie S. Chapter 21: Modelling the impact of HPV vaccines of cervical cancer and screening programmes. Vaccine 2006;24(S3):178-186.

  14. Goldie S, Kuhn L, Denny L, Pollack A, Wright T. Policy analysis of cervical cancer screening in low-resource settings, clinical benefits and cost-effectiveness. JAMA 2001;285:3107-3115.

  15. Goldie S, Kohli M, Grima D, Weinstein M, Wright T, Bosch F, Franco E. Projected clinical benefits and cost-effectiveness of a Human Papillomavirus 16/18 vaccine. J Nat Cancer Inst 2004;96:8.

  16. Goldie S, Kim J, Wright C. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Am Coll Obstetr Gynecol 2004;103:4.

  17. Goldie S, Gaffikin L, Goldhaber-Fiebert J, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005;353:2158-2168.

  18. Goldie S, Kim J, Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine 2006;24(suppl 3):164-170.

  19. Goldie S, Kim J, Kobus K, Goldhaber-Fiebert J, Salomon J, O’shea MK, et al. Cost-effectiveness of HPV 16,18 vaccination in Brazil. Vaccine 2007;25:33.

  20. Elbasha E, Dasbach E, Insigna R. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Disease 2007;13:1.

  21. Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Can Caus Cont 2003;14(6):505-512.

  22. Canadian Medical Association. Debate begins over public funding for HPV vaccine. Can Med Assoc J 2007;176(7).

  23. American Cancer Society. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. American Cancer Society, 2007. Disponible en: caonline. amcancersoc.org/egi/content/full/57/1/7. Consultado en marzo de 2007.

  24. Department of Health and Ageing. Australian Government funding of Gardasil. Australian Government: Department of Health and Ageing, 2006.

  25. Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Repor 2007;56(RR-2):1-24. .

  26. National Board of Health-Danish Centre for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV)-a health technology assessment, 2007. Disponible en: www.dacehta.dk/publications. Consultado en junio de 2007.

  27. Organización Mundial de la Salud. Preparación de la introducción de las vacunas contra el virus del papiloma humano, orientaciones normativas y programáticas para los países. Ginebra: Organización Mundial de la Salud, 2006.

  28. Sociedades Científicas de España. Vacunas profilácticas frente al VPH, documento de consenso de las sociedades científicas. Madrid: Sociedades Científicas de España, 2007.

  29. Centers for Disease Control and Prevention. Cervical Cancer Screening Guidelines. Disponible en: www.cdc.gov/cancer/cervical.

  30. Digene Corporation. HC2 HPV DNA Test, product insert. Disponible en: www.digene.com/healthcare/healthcare_products.html. Consultado en mayo de 2007.

  31. Flores S, Bishai F, Lazcano E, Shah P, Lorincz A, Hernandez M, Salmerón J. Improving cervical cancer screening in Mexico: results from the Morelos HPV Study. Salud Publica Mex 2003;45(suppl 3):S388-398.

  32. Cox T, Cuzick J. HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecol Oncol 2006;103:8-11.

  33. The University of Sheffield. Liquid-based citology in cervical screening: an updated rapid systematic review. Technology assessment report commissioned by the HTA Programme on behalf of The National Institute of Clinical Excellence. Sheffield: The University of Sheffield, 2003.

  34. Consejo Nacional de Población. Proyecciones poblacionales 2005- 2050. Disponible en: www.conapo.gob.mx. Consultado en mayo de 2007.

  35. Cichon M, Newbrander W, Yamabana H, Weber A, Normand Ch, Dror D, et al. Modelling in health care finance. United Kingdom: International Labour Office and International Social Security Association, 1999.

  36. González C, Rojas M, Hernández M, Oláiz G. Perfil del comportamiento sexual en adolescentes mexicanos de 12 a 19 años de edad: resultados de la ENSA 2000. Salud Publica Mex 2005;47(3).

  37. Martínez J, Belmonte J, Gascueña M, Caballero Ll, Sabroso C, García M. Cobertura e inmunorespuesta a la vacunación frente al virus de la Hepatitits B en adolescentes de la provincia de Guadalajara. Rev Esp Sal Pub 1998;72(2):119-126.

  38. Agosti J, Goldie S. Introducing HPV vaccine in developing countries-key challenges and issues. N Engl J Med 2007;356(19).

  39. Secretaría de Hacienda y Crédito Público. Cuenta de la Hacienda Pública Federal 2006. Disponible en: www.shcp.gob.mx. [Consultado junio 2007].

  40. Daniels N, Sabin J. Setting limits fairly: can we learn to share medical resources? United Kingdom: Oxford University Press, 2002.




2020     |     www.medigraphic.com